{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:18Z","timestamp":1790957538383,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.endien.2025.501562","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:23:02Z","timestamp":1747898582000},"page":"501562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1016","volume":"72","author":[{"given":"Fernando","family":"Garagoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Barbagelata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2025.501562_bib0195","doi-asserted-by":"crossref","first-page":"101082","DOI":"10.1016\/j.cpcardiol.2021.101082","article-title":"Peripheral arterial disease: a comprehensive updated review","volume":"47","author":"Shamaki","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.endien.2025.501562_bib0200","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11886-022-01677-6","article-title":"Contemporary medical therapies for patients with peripheral arterial disease and concomitant type 2 diabetes mellitus: a review of current evidence","volume":"24","author":"Narcisse","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.endien.2025.501562_bib0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2019.05.026","article-title":"Cost and inpatient burden of peripheral arterial disease: findings from the National Inpatient Sample","volume":"286","author":"Kohn","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.endien.2025.501562_bib0210","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061320","article-title":"New developments in pharmacological treatment of obesity and type 2 diabetes-beyond and within GLP-1 receptor agonists","volume":"12","author":"Sztanek","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.endien.2025.501562_bib0215","first-page":"e45487","article-title":"Role of Glucagon-Like Peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review","volume":"15","author":"Parab","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.endien.2025.501562_bib0220","doi-asserted-by":"crossref","first-page":"e3627","DOI":"10.1002\/dmrr.3627","article-title":"Pleiotropic effects of GLP-1 receptor agonists on peripheral arterial disease: is there any hope?","volume":"39","author":"Caruso","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.endien.2025.501562_bib0225","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc22-0772","article-title":"Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression","volume":"46","author":"Rodriguez-Valadez","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2025.501562_bib0230","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral arterial disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.endien.2025.501562_bib0235","doi-asserted-by":"crossref","first-page":"108390","DOI":"10.1016\/j.jdiacomp.2022.108390","article-title":"Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: a narrative review","volume":"37","author":"Liarakos","year":"2023","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.endien.2025.501562_bib0240","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.endien.2025.501562_bib0245","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.endien.2025.501562_bib0250","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.endien.2025.501562_bib0255","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2025.501562_bib0260","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2025.501562_bib0265","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER TRIAL","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2025.501562_bib0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2025.501562_bib0275","doi-asserted-by":"crossref","first-page":"e241545","DOI":"10.1001\/jamanetworkopen.2024.1545","article-title":"Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral arterial disease: the STARDUST randomized clinical trial","volume":"7","author":"Caruso","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.endien.2025.501562_bib0280","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2025.501562_bib0285","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2025.501562_bib0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2025.501562_bib0295","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2025.501562_bib0300","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2025.501562_bib0305","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2025.501562_bib0310","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2025.501562_bib0315","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjpc\/zwad381","article-title":"Global epidemiology of lower extremity artery disease in the 21st century (2000\u201321): a systematic review and meta-analysis","volume":"31","author":"Adou","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.endien.2025.501562_bib0320","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/diacare.24.8.1433","article-title":"Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome","volume":"24","author":"Jude","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2025.501562_bib0325","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-016-0446-x","article-title":"Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study","volume":"15","author":"Mohammedi","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.endien.2025.501562_bib0330","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1097\/MJT.0000000000001689","article-title":"Cardiovascular safety of glucagon-like receptor 1 agonists in patients with type 2 diabetes and peripheral arterial disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Ashraf","year":"2024","journal-title":"Am J Ther"},{"key":"10.1016\/j.endien.2025.501562_bib0335","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.endien.2025.501562_bib0340","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.atherosclerosis.2008.10.023","article-title":"Cardiovascular risk factor control and outcomes in peripheral arterial disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"204","author":"Cacoub","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.endien.2025.501562_bib0345","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11606-006-5042-4","article-title":"Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease","volume":"12","author":"McDermott","year":"1997","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.endien.2025.501562_bib0350","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1358863X221143811","article-title":"Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral arterial disease: a review","volume":"28","author":"Skeik","year":"2023","journal-title":"Vasc Med"},{"key":"10.1016\/j.endien.2025.501562_bib0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094633","article-title":"Novel therapeutical approaches to managing atherosclerotic risk","volume":"22","author":"Giglio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.endien.2025.501562_bib0360","doi-asserted-by":"crossref","first-page":"101909","DOI":"10.1016\/j.foot.2022.101909","article-title":"Health economics of diabetic foot ulcer and recent trends to accelerate treatment","volume":"52","author":"Jodheea-Jutton","year":"2022","journal-title":"Foot"},{"key":"10.1016\/j.endien.2025.501562_bib0365","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1177\/17085381211043952","article-title":"Effects of lipid-lowering therapy on major adverse limb events in patients with peripheral arterial disease: a meta-analysis of randomized clinical trials","volume":"30","author":"Masson","year":"2022","journal-title":"Vascular"},{"key":"10.1016\/j.endien.2025.501562_bib0370","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/dom.14361","article-title":"Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: a real-world study in two Italian cohorts","volume":"23","author":"Baviera","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2025.501562_bib0375","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.1016\/j.diabet.2022.101325","article-title":"Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.endien.2025.501562_bib0380","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:49:20Z","timestamp":1747900160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018025000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2530018025000587"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2025.501562","relation":{},"ISSN":["2530-0180"],"issn-type":[{"value":"2530-0180","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2025.501562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501562"}}